GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Debt-to-Revenue

Accelerate Diagnostics (STU:1A80) Debt-to-Revenue : 3.46 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Accelerate Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.16 Mil. Accelerate Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €35.02 Mil. Accelerate Diagnostics's annualized Revenue for the quarter that ended in Mar. 2024 was €10.75 Mil. Accelerate Diagnostics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 3.46.


Accelerate Diagnostics Debt-to-Revenue Historical Data

The historical data trend for Accelerate Diagnostics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Debt-to-Revenue Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.42 13.43 9.43 6.08 3.25

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.94 3.13 2.77 3.24 3.46

Competitive Comparison of Accelerate Diagnostics's Debt-to-Revenue

For the Medical Devices subindustry, Accelerate Diagnostics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Debt-to-Revenue falls into.



Accelerate Diagnostics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Accelerate Diagnostics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.096 + 33.868) / 11.058
=3.25

Accelerate Diagnostics's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.163 + 35.019) / 10.748
=3.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Accelerate Diagnostics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (STU:1A80) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines